Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy
Preprint
- 19 April 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
Neoadjuvant chemoimmunotherapy offers promise to improve outcomes for patients with resectable non-small cell lung cancer (NSCLC). Yet, not all patients derive treatment benefits and reliable biomarkers of response are still lacking. We here assess the long-term clinical outcome of neoadjuvant chemotherapy and perioperative anti-PD-L1 inhibition in resectable stage IIIA NSCLC in the SAKK 16/14 trial and provide a comprehensive characterization of anti-tumor immune responses for biomarker-based treatment personalization. At a median follow-up of 5.3 years, the median event-free survival (EFS) was 4.0 years while median overall survival was not reached. Computer-aided spatial image analysis emphasized the importance of CD8+ T cell positioning in tumors, and larger tertiary lymphoid structures in pre-treatment biopsies correlated with improved EFS. Genomic techniques revealed the association of intratumoral TCR diversity with response. Finally, circulating proliferating CD39+ PD-1+ CD8+ T cells and elevated levels of CCL15 post-treatment were seen in patients with sustained therapeutic benefit.Keywords
All Related Versions
- Version 1, 2024-04-19, Research Square
- Published version: Nature Communications, 16 (1), 1.
This publication has 55 references indexed in Scilit:
- LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLCAnnals of Oncology, 2023
- Establishing standardized immune phenotyping of metastatic melanoma by digital pathologyLaboratory Investigation, 2021
- Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancerNature Communications, 2021
- The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision supportCancer Cell, 2021
- Comprehensive T cell repertoire characterization of non-small cell lung cancerNature Communications, 2020
- Dissecting intratumoral myeloid cell plasticity by single cell RNA‐seqCancer Medicine, 2019
- Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)Journal of Thoracic Oncology, 2019
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2016
- Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trialThe Lancet, 2015
- Adjuvant chemotherapy for resected early-stage non-small cell lung cancerCochrane Database of Systematic Reviews, 2015